Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature

Case series Patient: Male, 35 • Male, 82 Final Diagnosis: Idiosyncratic DILI due to Ciprofloxacin Symptoms: Abdominal discomfort • fever • jaundice • nausea Medication: Ciprofloxacin Clinical Procedure: — Specialty: Gastroenterology and Hepatology Objective: Challenging differential diagnosis Background: Drug-induced liver injury (DILI) can present clinically as a spectrum that includes asymptomatic elevation of transaminases, acute or chronic hepatitis, and acute liver failure. Idiosyncratic DILI is more likely to affect individuals with comorbidities, and to have a wide range of clinical presentations. Although antibiotics are associated with DILI, the fluoroquinolone, ciprofloxacin, is a rarely reported cause. Two cases of idiosyncratic DILI following ciprofloxacin treatment are described, including a review of the literature. Case Report: Case 1: A 35-year-old man was treated with ciprofloxacin for periorbital cellulitis. On the second day of ciprofloxacin treatment, he developed abdominal pain, nausea, vomiting and increased serum levels of liver transaminases, aspartate aminotransferase (AST), and alanine aminotransferase (ALT). Further investigations excluded infectious hepatitis, autoimmune disease, or structural liver disease. Exclusion of other causes of DILI and cessation of ciprofloxacin resulted in clinical improvement and normalization of liver function tests (LFTs). Case 2: An 82-year-old man was treated with ciprofloxacin for osteomyelitis. On the tenth day of ciprofloxacin treatment, he developed jaundice and abnormal LFTs, including increased AST, ALT, alkaline phosphatase (ALP), and total bilirubin. Further investigations excluded infectious hepatitis, autoimmune disease, or structural liver disease. Exclusion of other causes of DILI and cessation of ciprofloxacin resulted in clinical improvement and normalization of LFTs. Conclusions: Idiosyncratic DILI due to ciprofloxacin treatment is rare. These two cases have shown that timely diagnosis and discontinuation of ciprofloxacin can prevent the progression of DILI, reduce liver damage, and reduce mortality rates from DILI.

[1]  P. Ganey,et al.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  James H. Lewis,et al.  The rational use of potentially hepatotoxic medications in patients with underlying liver disease , 2002, Expert opinion on drug safety.

[3]  J. Beizer,et al.  Possible Ciprofloxacin-Induced Acute Cholestatic Jaundice , 1994, The Annals of pharmacotherapy.

[4]  M. Brezis,et al.  Fatal hepatic failure associated with ciprofloxacin , 1994, The Lancet.

[5]  Layth Al-Jashaami,et al.  Ciprofloxacin Exposure Leading to Fatal Hepatotoxicity: An Unusual Correlation , 2016, The American journal of case reports.

[6]  Michael Merz,et al.  Drug-induced liver injury: recent advances in diagnosis and risk assessment , 2017, Gut.

[7]  William M. Lee Drug-induced acute liver failure. , 2013, Clinics in liver disease.

[8]  William M. Lee,et al.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. , 2014, Gastroenterology.

[9]  E. Cholongitas,et al.  Ciprofloxacin-induced acute cholestatic hepatitis. , 2009, Annals of hepatology.

[10]  G. Klőppel,et al.  Cholestatic hepatitis related to quinolones: a report of two cases. , 1995, Journal of hepatology.

[11]  Z. Goodman,et al.  Ciprofloxacin-induced acute cholestatic liver injury and associated renal failure. Case report and review. , 2008, Minerva gastroenterologica e dietologica.

[12]  M. Raza,et al.  Ciprofloxacin-induced Hepatotoxicity in a Healthy Young Adult , 2017, Cureus.

[13]  M. Goetz,et al.  Non-Fatal Acute Liver Injury Possibly Related to High-Dose Ciprofloxacin , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[14]  T. Alempijevic,et al.  Drug-induced liver injury: Do we know everything? , 2017, World journal of hepatology.

[15]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[16]  R. Fontana,et al.  An update on drug induced liver injury. , 2011, Minerva gastroenterologica e dietologica.

[17]  S. Zaidi Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin. , 2003, The American journal of the medical sciences.

[18]  Muhammad M Mamdani,et al.  Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study , 2012, Canadian Medical Association Journal.

[19]  A. Geubel,et al.  Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. , 2002, Journal of hepatology.

[20]  V. Lehr,et al.  Fulminant Hepatic Failure Possibly Related to Ciprofloxacin , 1992, The Annals of pharmacotherapy.

[21]  M. Alcalde,et al.  Liver disfunction due to ciprofloxacin. , 1995, Acta gastro-enterologica Belgica.

[22]  M. Vergara,et al.  Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic. , 2015, Revista Espanola de Enfermedades Digestivas.

[23]  R. Fontana,et al.  The diagnosis and management of idiosyncratic drug‐induced liver injury , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[24]  H. Kurt,et al.  Unexpected severe hepatotoxicity of ciprofloxacine: two case reports , 2011, Drug and chemical toxicology.

[25]  L. Terracciano,et al.  Ciprofloxacin-induced acute liver injury: case report and review of literature , 2003, Virchows Archiv.

[26]  R. Andrade,et al.  Hepatic safety of antibiotics used in primary care , 2011, The Journal of antimicrobial chemotherapy.

[27]  R. Fontana,et al.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.

[28]  S. Olafsson,et al.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. , 2013, Gastroenterology.

[29]  N. Høiby,et al.  The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. , 1987, The Journal of antimicrobial chemotherapy.

[30]  L. Zechiedrich,et al.  Wicked: The untold story of ciprofloxacin , 2018, PLoS pathogens.

[31]  K. Bhagirath A case report of highly suspected ciprofloxacin-induced hepatotoxicity. , 2008, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[32]  G. Joshi,et al.  Ciprofloxacin-induced cholestatic jaundice. , 2007, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[33]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver injury. , 2013, Clinics in liver disease.

[34]  William M. Lee,et al.  ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury , 2014, The American Journal of Gastroenterology.

[35]  J. Andreu,et al.  Severe Ciprofloxacin-Induced Acute Hepatitis , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[36]  H. Conjeevaram,et al.  Clinical and histopathologic features of fluoroquinolone-induced liver injury. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  M. Maes,et al.  Drug-induced liver injury: mechanisms, types and biomarkers. , 2013, Current medicinal chemistry.

[38]  D. Harnois Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States , 2009 .

[39]  Y. Sammour,et al.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature , 2018, The American journal of case reports.

[40]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[41]  D. Adams,et al.  Mechanisms of immune-mediated liver injury. , 2010, Toxicological Sciences.

[42]  H. Baba,et al.  Idiosyncratic drug‐induced liver injury: A short review , 2017, Hepatology communications.

[43]  R. Andrade,et al.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. , 2007, World Journal of Gastroenterology.

[44]  J. Uetrecht,et al.  Immunoallergic Drug-Induced Liver Injury in Humans , 2009, Seminars in liver disease.

[45]  J. Gurka,et al.  Probable ciprofloxacin induced cholestasis. , 1995, Australian and New Zealand journal of medicine.

[46]  C. Bénichou Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[47]  N. Chalasani,et al.  Risk factors for idiosyncratic drug-induced liver injury. , 2010, Gastroenterology.

[48]  William M. Lee,et al.  Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. , 2009, Gastroenterology.

[49]  Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. , 1990, International journal of clinical pharmacology, therapy, and toxicology.

[50]  Luis Rodrigo,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[51]  P. Tulkens,et al.  Terms and Conditions for Use of Pdf , 2022 .

[52]  W. Silverman,et al.  Cholestatic jaundice induced by ciprofloxacin. , 1997, Digestive diseases and sciences.

[53]  J. Villeneuve,et al.  Suspected Ciprofloxacin-Induced Hepatotoxicity , 1995, The Annals of pharmacotherapy.